10
« -: Април 10, 2013, 23:46:02 »
Здравей Руми,
В един журнал намерих тази информация:
A Single-Shot-Cure for Hepatitis C Being Tested at Duke
March 28, 2013
A potential single-injection-cure for Hepatitis C, Benitec’s revolutionary TT-034 will soon be tested in previous non-responders at Duke Clinical Research Institute.
Duke Clinical Research Unit to Conduct Hepatitis C Clinical Trial
Friday, March 22, 2013
RNAi-based therapeutics company Benitec Biopharma Limited announced Duke Clinical Research Unit, the early phase unit of the Duke Clinical Research Institute (DCRI), in Durham, North Carolina, as a site for its upcoming phase I/II first-in-man trial for TT-034 in Hepatitis C. TT-034 is being developed as a potential “one-shot-cure” for Hepatitis C (HCV).
SYDNEY and DURHAM, NC — “We are very excited to be working with Duke, a world renowned research institution with significant experience in this area,” said Peter French, Ph.D., Chief Executive Officer of Benitec. “The TT-034 trial marks the transition of Benitec to a clinical stage company. We expect that positive results from the trial will provide a value inflection point for the company, and also be a validation for our ddRNAi technology as an effective platform for therapeutics.”
Да, малко неясно съм се изразила, но поправих текста си. Приключих лечението си и на първи, трети и шести месец след него, вирусът не се открива.
При мен лечението мина много леко и се чувствам добре. Не знам точно какво те интересува, ако е необходимо ми прати личен имейл. Желая ти от все сърце същия резултат!
Публикации - Walmsley
